Inhibikase Therapeutics Inc (IKT NASDAQ) stock market data APIs
$1.9531
0(0%)
as of July 1, 2025
Try our APIs with
free plan!
Inhibikase Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Prev. Close
1.9531
Open
1.9531
High
1.9694
Low
1.8219
52 wk Range
1.12-4.2
Market Cap
145 M
Shares Outstanding
74 342 K
Revenue
1
EPS
-0.15
Beta
0.945
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inhibikase Therapeutics Inc data using free add-ons & libraries
Get Inhibikase Therapeutics Inc Fundamental Data
Inhibikase Therapeutics Inc Fundamental data includes:
- Net Revenue: 1
- EBITDA: -39 537 220
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-06
- EPS/Forecast: -0.095
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibikase Therapeutics Inc News
New
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes
Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company currently trading near $1.95 and showing a strong 17.47% gain over the past week, held its 2025 Annual Meeting of Stockholders on F...
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director
Ludwig Enterprises, Inc. (OTC:LUDG) announced the appointment of Garth Lees-Rolfe as an independent director, effective Monday. The decision was made by the company’s board of directors and was disc...
Inhibikase Therapeutics files $300M mixed securities shelf
* Inhibikase Therapeutics (NASDAQ:IKT [https://seekingalpha.com/symbol/IKT]) filed $300M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10116244] MORE ON INHIBIKASE THERAPEUTIC...
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecul...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
